In the past year, generative artificial intelligence (GAI) has emerged as a potentially groundbreaking force in the pharmaceutical industry. This technology, which involves AI systems that can generate novel data and insights, could very well become transformative in the way drugs are discovered, developed, and brought to market.
Generative AI marks a paradigm shift in pharmaceutical research, ushering in an era where the power of advanced algorithms and machine learning techniques accelerates and refines the drug discovery process. Unlike traditional methods, which rely heavily on trial and error, generative AI can analyse vast datasets, predict the efficacy of compounds, and even propose novel drug candidates with higher precision and at a fraction of the time and cost.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
